tbuckley/cabot-search huggingface dataset:
Trends in Trauma Admissions During the COVID-19 Pandemic in Los Angeles County, California
Authors: Cameron Ghafil, Kazuhide Matsushima, Li Ding, Reynold Henry, Kenji Inaba
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Describing the changes in trauma volume and injury patterns during the course of the coronavirus disease 2019 (COVID-19) pandemic could help to inform policy development and hospital resource planning. <h3>Objective</h3> To examine trends in trauma admissions throughout Los Angeles County (LAC) during the pandemic. <h3>Design, Setting, and Participants</h3> In this cohort study, all trauma admissions to the 15 verified level 1 and level 2 trauma centers in LAC from January 1 to June 7, 2020 were reviewed. All trauma admissions from the same period in 2019 were used as historical control. For overall admissions, the study period was divided into 3 intervals based on daily admission trend analysis (January 1 through February 28, March 1 through April 9, April 10 through June 7). For the blunt trauma subgroup analysis, the study period was divided into 3 similar intervals (January 1 through February 27, February 28 through April 5, April 6 through June 7). <h3>Exposures</h3> COVID-19 pandemic. <h3>Main Outcomes and Measures</h3> Trends in trauma admission volume and injury patterns. <h3>Results</h3> A total of 6777 patients in 2020 and 6937 in 2019 met inclusion criteria. Of those admitted in 2020, the median (interquartile range) age was 42 (28-61) years and 5100 (75.3%) were men. Mechanisms of injury were significantly different between the 2 years, with a higher incidence of penetrating trauma and fewer blunt injuries in 2020 compared with 2019 (penetrating: 1065 [15.7%] vs 1065 [15.4%]; blunt: 5309 [78.3%] vs 5528 [79.7%]). Overall admissions by interval in 2020 were 2681, 1684, and 2412, whereas in 2019 they were 2462, 1862, and 2613, respectively. There was a significant increase in overall admissions per week during the first interval (incidence rate ratio [IRR], 1.02; 95% CI, 1.002-1.04;<i>P</i> = .03) followed by a decrease in the second interval (IRR, 0.92; 95% CI, 0.90-0.94;<i>P</i> &lt; .001) and, finally, an increase in the third interval (IRR, 1.05; CI, 1.03-1.07;<i>P</i> &lt; .001). On subgroup analysis, blunt admissions followed a similar pattern to overall admissions, while penetrating admissions increased throughout the study period. <h3>Conclusions and Relevance</h3> In this study, trauma centers throughout LAC experienced a significant change in injury patterns and admission trends during the COVID-19 pandemic. A transient decrease in volume was followed by a quick return to baseline levels. Trauma centers should prioritize maintaining access, capacity, and functionality during pandemics and other national emergencies.
Abstract 15219: Beta-Adrenergic Reserve in the Left Ventricular Systolic Function in Kawasaki Disease Patients With Regressed Coronary Arterial Lesions May Be Limited, in Part, Because of Impaired Coronary Reserve
Authors: Satoshi Masutani, Hirofumi Saiki, Yoichi Iwamoto, Hirotaka Ishido, Hideaki Senzaki
Journal: Circulation (2018)

Introduction: Although coronary flow reserve (CFR) and endothelial function are impaired in Kawasaki disease (KD) patients with regressed coronary arterial legions (CAL), load-insensitive cardiovas...
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Authors: Scott M. Grundy, Neil J. Stone, Alison L. Bailey, Craig Beam, Kim K. Birtcher, Roger S. Blumenthal, Lynne T. Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E. Forman, Ronald Goldberg, Paul A. Heidenreich, Mark A. Hlatky, Daniel W. Jones, Donald Lloyd-Jones, Nuria Lopez-Pajares, Chiadi E. Ndumele, Carl E. Orringer, Carmen A. Peralta, Joseph J. Saseen, Sidney C. Smith, Laurence Sperling, Salim S. Virani, Joseph Yeboah
Journal: Journal of the American College of Cardiology (2018)
Divergent pallidal pathways underlying distinct Parkinsonian behavioral deficits
Authors: Varoth Lilascharoen, Eric Hou-Jen Wang, Nam Do, Stefan Carl Pate, Amanda Ngoc Tran, Christopher Dabin Yoon, Jun-Hyeok Choi, Xiao-Yun Wang, Horia Pribiag, Young-Gyun Park, Kwanghun Chung, Byung Kook Lim
Journal: Nature Neuroscience (2021)
Large-scale ICU data sharing for global collaboration: the first 1633 critically ill COVID-19 patients in the Dutch Data Warehouse
Authors: Lucas M. Fleuren, Daan P. de Bruin, Michele Tonutti, Robbert C. A. Lalisang, Paul W. G. Elbers
Journal: Intensive Care Medicine (2021)

The coronavirus disease 2019 (COVID-19) pandemic continues to stretch intensive care unit (ICU) capacity to its limits worldwide and optimizing management of critically ill COVID-19 patients remains urgently needed [1].Fortunately, most ICUs deploy Electronic Health Records (EHRs) to routinely capture high-frequency clinical information.These data reflect the clinical practice variation resulting from the novelty of COVID-19 as well as the variation in patient characteristics and outcomes between centers [2, 3].Therefore, these data may be employed to better understand the clinical course of COVID-19 and individualize treatment.Given these considerations, a large-scale ICU data sharing collaboration in The Netherlands was initiated for the COVID-19 pandemic, resulting in the Dutch Data Warehouse (DDW, Fig. 1).While the database is growing, at this point, the DDW combines pseudonymized EHR data from 23 intensive care units covering the entire ICU admission of all adult COVID-19 patients treated in these ICUs.Collected data include data from monitoring and life support devices, demographics, medication, fluid balance, comorbidities, laboratory results, and outcomes.All parameters were manually reviewed by intensive care
A Library for Internists IV
Authors: RICHARD ALLYN
Journal: Annals of Internal Medicine (1982)

The Literature of Medicine1 March 1982A Library for Internists IVRecommended by the American College of PhysiciansRICHARD ALLYN, M.D.RICHARD ALLYN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-3-385 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThis new and current comprehensive list of books and journals has been developed, like its predecessors (1-3), on the premise that recommendations made by many authorities in each field will be a more reliable guide to the most useful books and journals for internists than recommendations made by only a few persons (4,5). From this list an internist or a librarian can select a few "core" texts and journals for a personal library or a small hospital library or can select a comprehensive set of reference texts and journals for a larger library. Recommendations are in general internal medicine, 10...References1. ALLYNSTEARNS RN. A library for internists: recommended by the American College of Physicians. Ann Intern Med. 1973;79:293-322. LinkGoogle Scholar2. ALLYN R. A library for internists II: recommended by the American College of Physicians. Ann Intern Med. 1976;84:346-73. LinkGoogle Scholar3. ALLYN R. A library for internists III: recommended by the American College of Physicians. Ann Intern Med. 1979;90:446-77. LinkGoogle Scholar4. BRANDONHILL AD. Selected list of books and journals for the small medical library. Bull Med Libr Assoc. 1981;69:185-215. MedlineGoogle Scholar5. WESTWENDERMAY KRR. Books in clinical practice 1971-1975. Postgrad Med. 1974;56:60-81. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Springfield, Illinois▸Dr. Allyn is Chairman, Committee on A Library for Internists IV, American College of Physicians Educational Activities Committee, Philadelphia, Pennsylvania; and Clinical Professor of Medicine, Southern Illinois University School of Medicine, Springfield, Illinois.The other members of the Committee on A Library for Internists IV are E. Richard Ensrud, M.D.,; Blair D. Erb, M.D.,; Norton J. Greenberger, M.D.; Paul A. Haber, M.D.; Edward J. Huth, M.D.; Ceylon S. Lewis, Jr., M.D.; and Robert C. Schlant, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byA Library for Internists VII Recommendations from the American College of PhysiciansKenneth M. Ludmerer, MDA Library for Internists VI Recommendations from the American College of PhysiciansEdward J. Huth, M.D., EditorA Library for Internists V Recommended by the American College of PhysiciansC. S. LEWIS Jr., M.D.A new library for emergency medicine 1 March 1982Volume 96, Issue 3Page: 385-386KeywordsLibraries Issue Published: 1 March 1982 PDF downloadLoading ...
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis
Authors: Cathrin L.C. Gudd, Lewis Au, Evangelos Triantafyllou, Benjamin Shum, Tong Liu, Rooshi Nathwani, Naveenta Kumar, Sujit Mukherjee, Ameet Dhar, Kevin J. Woollard, You Yone, David J. Pinato, Mark R. Thursz, Robert D. Goldin, Martin E. Gore, James Larkin, Wafa Khamri, Charalambos G. Antoniades, Samra Turajlic, Lucia A. Possamai
Journal: Journal of Hepatology (2021)

Checkpoint inhibitor-related hepatitis (CPI-Hep) is an emerging clinical challenge. We aimed to gain insights into the immunopathology of CPI-Hep by comprehensively characterising myeloid and lymphoid subsets.
Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
Authors: Siddharth Singh, Herbert C. Heien, Jeph Herrin, Parambir S. Dulai, Lindsey Sangaralingham, Nilay D. Shah, William J. Sandborn
Journal: Clinical Gastroenterology and Hepatology (2021)
ReSeq simulates realistic Illumina high-throughput sequencing data
Authors: Stephan Schmeing, Mark D. Robinson
Journal: Genome biology (2021)

Abstract In high-throughput sequencing data, performance comparisons between computational tools are essential for making informed decisions at each step of a project. Simulations are a critical part of method comparisons, but for standard Illumina sequencing of genomic DNA, they are often oversimplified, which leads to optimistic results for most tools. ReSeq improves the authenticity of synthetic data by extracting and reproducing key components from real data. Major advancements are the inclusion of systematic errors, a fragment-based coverage model and sampling-matrix estimates based on two-dimensional margins. These improvements lead to more faithful performance evaluations. ReSeq is available at https://github.com/schmeing/ReSeq .
Association of History of Psychopathology With Accelerated Aging at Midlife
Authors: Jasmin Wertz, Avshalom Caspi, Antony Ambler, Jonathan Broadbent, Robert J. Hancox, HonaLee Harrington, Sean Hogan, Renate M. Houts, Joan H. Leung, Richie Poulton, Suzanne C. Purdy, Sandhya Ramrakha, Line Jee Hartmann Rasmussen, Leah S. Richmond-Rakerd, Peter R. Thorne, Graham A. Wilson, Terrie E. Moffitt
Journal: JAMA Psychiatry (2021)

Individuals with mental disorders are at an elevated risk of developing chronic age-related physical diseases. However, it is not clear whether psychopathology is also associated with processes of accelerated aging that precede the onset of age-related disease.To test the hypothesis that a history of psychopathology is associated with indicators of accelerated aging at midlife.This prospective cohort study was based on the Dunedin Multidisciplinary Health and Development Study, a population-representative birth cohort of 1037 individuals born between April 1, 1972, and March 31, 1973, in Dunedin, New Zealand. Members were followed up to age 45 years (until April 2019). Data were analyzed from January 6 to December 7, 2020.Mental disorders were assessed in 6 diagnostic assessments from ages 18 to 45 years and transformed through confirmatory factor analysis into continuous measures of general psychopathology (p-factor) and dimensions of internalizing, externalizing, and thought disorders (all standardized to a mean [SD] of 100 [15]).Signs of aging (biological pace of aging; declines in sensory, motor, and cognitive functioning; and facial age) were assessed up to age 45 years using previously validated measures including biomarkers, clinical tests, and self-reports.Of the original 1037 cohort participants, 997 were still alive at age 45 years, of whom 938 (94%) were assessed (474 men [50.5%]). Participants who had experienced more psychopathology exhibited a faster pace of biological aging (β, 0.27; 95% CI, 0.21-0.33; P < .01); experienced more difficulties with hearing (β, 0.18; 95% CI, 0.12-0.24; P < .01), vision (β, 0.08; 95% CI, 0.01-0.14; P < .05), balance (β, 0.20; 95% CI, 0.14-0.26; P < .01), and motor functioning (β, 0.19; 95% CI, 0.12-0.25; P < .01); experienced more cognitive difficulties (β, 0.24; 95% CI, 0.18-0.31; P < .01); and were rated as looking older (β, 0.20; 95% CI, 0.14-0.26; P < .01). Associations persisted after controlling for sex, childhood health indicators, maltreatment, and socioeconomic status and after taking into account being overweight, smoking, use of antipsychotic medication, and the presence of physical disease. Tests of diagnostic specificity revealed that associations were generalizable across externalizing, internalizing, and thought disorders.In this cohort study, a history of psychopathology was associated with accelerated aging at midlife, years before the typical onset of age-related diseases. This link is not specific to any particular disorder family but generalizes across disorders. Prevention of psychopathology and monitoring of individuals with mental disorders for signs of accelerated aging may have the potential to reduce health inequalities and extend healthy lives.
Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity
Authors: Zijing Zhang, Zuo Du, Qinhui Liu, Tong Wu, Qin Tang, Jinhang Zhang, Cuiyuan Huang, Ya Huang, Rui Li, Yanping Li, Yingnan Zhao, Guorong Zhang, Jian Zhou, Hui Huang, ZhongZe Fang, Jinhan He
Journal: Metabolism (2021)
Warming Up to Cold Perfusion
Authors: Winfred W. Williams, James F. Markmann
Journal: New England Journal of Medicine (2021)

Each year, thousands of people in the United States die while awaiting lifesaving liver transplantation because there is an insufficient supply of donor organs. This crisis has prompted increased interest in expanding the organ supply through the promotion of both deceased and live liver donation and has led to the encouragement of use of organs from so-called expanded-criteria donation — grafts from older donors, grafts with suboptimal organ quality (e.g., with varying degrees of fatty liver deposits or steatosis), or grafts that had sustained prolonged ischemia times after they were obtained. Livers from deceased donors that are obtained after circulatory . . .
Preventing Opioid-Induced Constipation—Reply
Authors: Srishti Saha, Piyush Nathani, Arjun Gupta
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Authors: Andrea DeCensi, Matteo Puntoni, Harriet Johansson, Aliana Guerrieri-Gonzaga, Silvia Caviglia, Franca Avino, Laura Cortesi, Antonio Ponti, Maria Grazia Pacquola, Fabio Falcini, Marcella Gulisano, Maria Digennaro, Anna Cariello, Katia Cagossi, Graziella Pinotti, Matteo Lazzeroni, Davide Serrano, Irene Maria Briata, Tania Buttiron Webber, Luca Boni, Bernardo Bonanni
Journal: Clinical Cancer Research (2021)

Abstract Purpose: Low-dose tamoxifen halved recurrence after surgery in a phase III trial in breast noninvasive disease without increasing adverse events. We explored the effect of low-dose tamoxifen in clinically relevant subgroups, including menopausal status, estradiol levels, smoking, body mass index, and proliferation of baseline lesion. Patients and Methods: Incidence of invasive breast cancer or ductal carcinoma in situ was the primary endpoint. HRs and interaction terms were estimated using Cox models. Results: A favorable HR and 95% confidence interval (CI) could be demonstrated for postmenopausal status (HR = 0.30; 95% CI, 0.11–0.82 vs. HR = 0.73; 95% CI, 0.30–1.76 in premenopausal women; Pinteraction = 0.13), women with estradiol less than 15.8 pg/mL, presence of menopausal symptoms at baseline, and never smoking (Pinteraction = 0.07), although the interaction P value was &amp;gt;0.05 for all characteristics. Efficacy was similar in all body mass index categories. Tumors with Ki-67 above the median level of 10% had a greater benefit (HR = 0.27; 95% CI, 0.09–0.81) than those with Ki-67 ≤10% (HR = 1.58; 95% CI, 0.45–5.60; Pinteraction = 0.04). Conclusions: The efficacy of low-dose tamoxifen seems to be greater in postmenopausal women and in women with lower estradiol levels. Benefits appear to be larger also in women with menopausal symptoms, never smokers, and tumors with Ki-67 &amp;gt;10%. Our results by menopausal status provide important insight into low-dose tamoxifen personalized treatment, although caution is necessary given their exploratory nature. Observation of an improved response in tumors with Ki-67 &amp;gt;10% is consistent but the use of the marker in this setting is investigational. See related commentary by Fabian, p. 3510
<i>CARMN</i> Loss Regulates Smooth Muscle Cells and Accelerates Atherosclerosis in Mice
Authors: Francesca Vacante, Julie Rodor, Mukesh K. Lalwani, Amira D. Mahmoud, Matthew Bennett, Azzurra L. De Pace, Eileen Miller, Kim Van Kuijk, Jenny de Bruijn, Marion Gijbels, Thomas C. Williams, Michael B. Clark, Jessica P. Scanlon, Amanda C. Doran, Rusty Montgomery, David E. Newby, Mauro Giacca, Dónal O’Carroll, Patrick W.F. Hadoke, Laura Denby, Judith C. Sluimer, Andrew H. Baker
Journal: Circulation Research (2021)

[Figure: see text].
Association of High-Density Lipoprotein Cholesterol With Sex Steroid Treatment in Transgender and Gender-Diverse Youth
Authors: Kate Millington, Courtney Finlayson, Johanna Olson-Kennedy, Robert Garofalo, Stephen M. Rosenthal, Yee-Ming Chan
Journal: JAMA Pediatrics (2021)

This cohort study analyzes the association of sex steroids with cholesterol in different sex-chromosome contexts.
The effect of prophylaxis with ertapenem versus cefuroxime/metronidazole on intestinal carriage of carbapenem-resistant or third-generation-cephalosporin-resistant Enterobacterales after colorectal surgery
Authors: Tomer Hoffman, Jonathan Lellouche, Amir Nutman, Elizabeth Temkin, Sammy Frenk, Stephan Harbarth, Biljana Carevic, Shimrit Cohen-Percia, Yehuda Kariv, Noga Fallach, Joseph Klausner, Yehuda Carmeli
Journal: Clinical Microbiology and Infection (2021)
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Authors: Ivan O Rosas, Norbert Bräu, Michael Waters, Ronaldo C Go, Bradley D Hunter, Sanjay Bhagani, Daniel Skiest, Mariam S Aziz, Nichola Cooper, Ivor S Douglas, Sinisa Savic, Taryn Youngstein, Lorenzo Del Sorbo, Antonio Cubillo Gracian, David J De La Zerda, Andrew Ustianowski, Min Bao, Sophie Dimonaco, Emily Graham, Balpreet Matharu, Helen Spotswood, Larry Tsai, Atul Malhotra
Journal: New England Journal of Medicine (2021)

Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and retrospective observational cohort studies. Data are needed from randomized, placebo-controlled trials.In this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of tocilizumab (at a dose of 8 mg per kilogram of body weight) or placebo. Approximately one quarter of the participants received a second dose of tocilizumab or placebo 8 to 24 hours after the first dose. The primary outcome was clinical status at day 28 on an ordinal scale ranging from 1 (discharged or ready for discharge) to 7 (death) in the modified intention-to-treat population, which included all the patients who had received at least one dose of tocilizumab or placebo.Of the 452 patients who underwent randomization, 438 (294 in the tocilizumab group and 144 in the placebo group) were included in the primary and secondary analyses. The median value for clinical status on the ordinal scale at day 28 was 1.0 (95% confidence interval [CI], 1.0 to 1.0) in the tocilizumab group and 2.0 (non-ICU hospitalization without supplemental oxygen) (95% CI, 1.0 to 4.0) in the placebo group (between-group difference, -1.0; 95% CI, -2.5 to 0; P = 0.31 by the van Elteren test). In the safety population, serious adverse events occurred in 103 of 295 patients (34.9%) in the tocilizumab group and in 55 of 143 patients (38.5%) in the placebo group. Mortality at day 28 was 19.7% in the tocilizumab group and 19.4% in the placebo group (weighted difference, 0.3 percentage points; 95% CI, -7.6 to 8.2; nominal P = 0.94).In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. (Funded by F. Hoffmann-La Roche and the Department of Health and Human Services; COVACTA ClinicalTrials.gov number, NCT04320615.).
発癌性変化は調節性T細胞への代謝優位性を与えることにより腫瘍進行を促進する微小環境を創造する【JST・京大機械翻訳】
Authors: Kumagai Shogo, Togashi Yosuke, Sakai Chika, Kawazoe Akihito, Kawazu Masahito, Ueno Toshihide, Sato Eiichi, Kuwata Takeshi, Kinoshita Takahiro, Yamamoto Masami, Nomura Sachiyo, Tsukamoto Tetsuya, Mano Hiroyuki, Shitara Kohei, Nishikawa Hiroyoshi
Journal: Immunity (2020)
Abstract 14638: Giant Coronary Artery Aneurysms: An Unusual Case of STEMI
Authors: Harshith S Thyagaturu, Farah Deshmukh, Sandeep Mangalmurti
Journal: Circulation (2019)

Background: Coronary Artery Aneurysm (CAA) is a rare finding with an incidence of about 0.3 to 5.3%. CAA is defined as the localized dilation of coronary artery more than 1.5 times the normal diame...